Li Pengtao, Axier Aximujiang, Li Shaoshan, Zhou Kai, Yun Jingwei, Wang Huayi, Zhang Tingrong
Department of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.
Medicine (Baltimore). 2020 Dec 4;99(49):e22995. doi: 10.1097/MD.0000000000022995.
Craniopharyngioma is the most challenging brain tumor with a high recurrence rate. Some scholars have shown that endoscopic endonasal approach (EEA) can achieve a higher total tumor resection rate and significantly reduce the incidence of complications and mortality. However, there is still no consensus on the surgical approach for recurrent craniopharyngioma. The purpose of this study is to evaluate the safety and efficacy of EEA in the treatment of recurrent craniopharyngioma.
We will search 7 electronic databases (PubMed, EMBASE, Web of Science, the Cochrane Library, PsycINFO, AMED, Scopus) to collect related randomized controlled trials (RCTs). The resection rate, recurrence rate and progression-free survival rate will be regarded as the primary outcome, and the incidence of complications will be regarded as the secondary outcome. Endnote Software X9.0 will be used to filter articles, Review Manager Software 5.2 and STATA software 16.0 will be used for analysis and synthesis.
We will integrate existing studies to assess the safety and efficacy of EEA in the treatment of recurrent craniopharyngioma.
Our study will provide EEA as an effective and safe treatment for recurrent craniopharyngioma.
International Prospective Register of Systematic Reviews (PROSPERO): CRD42020199860.
颅咽管瘤是最具挑战性的脑肿瘤,复发率高。一些学者表明,内镜鼻内入路(EEA)可实现更高的肿瘤全切除率,并显著降低并发症发生率和死亡率。然而,对于复发性颅咽管瘤的手术入路仍未达成共识。本研究的目的是评估EEA治疗复发性颅咽管瘤的安全性和有效性。
我们将检索7个电子数据库(PubMed、EMBASE、科学网、考克兰图书馆、PsycINFO、AMED、Scopus)以收集相关随机对照试验(RCT)。切除率、复发率和无进展生存率将被视为主要结局,并发症发生率将被视为次要结局。将使用Endnote软件X9.0筛选文章,使用Review Manager软件5.2和STATA软件16.0进行分析和综合。
我们将整合现有研究,以评估EEA治疗复发性颅咽管瘤的安全性和有效性。
我们的研究将为复发性颅咽管瘤提供EEA这种有效且安全的治疗方法。
国际系统评价前瞻性注册库(PROSPERO):CRD42020199860。